{
    "ticker": "VYNE",
    "name": "VYNE Therapeutics Inc.",
    "description": "VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. Founded in 2017 and headquartered in New York, VYNE is dedicated to advancing its proprietary, innovative drug delivery technologies and product candidates, particularly in the fields of dermatology and immunology. The company\u2019s lead product candidate, VYNE-001, is aimed at treating inflammatory skin diseases. VYNE employs a unique approach by utilizing its proprietary technology platform, which includes the use of micro-emulsions and topical formulations, to enhance the efficacy and safety of its therapeutic products. The company is committed to improving patient outcomes and providing effective treatment options for patients suffering from various skin conditions. VYNE\u2019s focus on innovation and patient-centered solutions sets it apart in the competitive biopharmaceutical landscape. The company is actively engaged in clinical trials and research to expand its portfolio and bring new therapies to market, reflecting its mission to transform the treatment paradigm in dermatological care.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2017",
    "website": "https://www.vynetherapeutics.com",
    "ceo": "David Domzalski",
    "social_media": {
        "twitter": "https://twitter.com/VYNETherapeutics",
        "linkedin": "https://www.linkedin.com/company/vyne-therapeutics"
    },
    "investor_relations": "https://ir.vynetherapeutics.com",
    "key_executives": [
        {
            "name": "David Domzalski",
            "position": "CEO"
        },
        {
            "name": "G. Kelly Martin",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Product Candidates",
            "products": [
                "VYNE-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "VYNE Therapeutics Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for dermatological and immunological conditions.",
        "keywords": [
            "VYNE Therapeutics",
            "biopharmaceuticals",
            "dermatology",
            "immunology",
            "VYNE-001"
        ]
    },
    "faq": [
        {
            "question": "What does VYNE Therapeutics focus on?",
            "answer": "VYNE Therapeutics focuses on developing innovative therapies for dermatological and immunological conditions."
        },
        {
            "question": "Where is VYNE Therapeutics headquartered?",
            "answer": "VYNE Therapeutics is headquartered in New York, New York, USA."
        },
        {
            "question": "What is VYNE-001?",
            "answer": "VYNE-001 is VYNE's lead product candidate aimed at treating inflammatory skin diseases."
        },
        {
            "question": "When was VYNE Therapeutics founded?",
            "answer": "VYNE Therapeutics was founded in 2017."
        }
    ],
    "competitors": [
        "PTCT",
        "VRTX",
        "AMGN",
        "REGN"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}